ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock.

IBRX has been the topic of a number of other research reports. BTIG Research started coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective on the stock. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Stock Down 1.6 %

Shares of NASDAQ:IBRX opened at $3.08 on Monday. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -3.35 and a beta of 0.86. The company has a 50 day moving average of $3.43 and a two-hundred day moving average of $4.03. ImmunityBio has a 52-week low of $2.28 and a 52-week high of $10.53.

Institutional Trading of ImmunityBio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Stephens Inc. AR bought a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $26,000. Captrust Financial Advisors bought a new stake in ImmunityBio during the third quarter valued at $41,000. Mutual Advisors LLC bought a new stake in ImmunityBio during the fourth quarter valued at $41,000. Virtu Financial LLC bought a new position in shares of ImmunityBio in the 3rd quarter worth about $51,000. Finally, Algert Global LLC acquired a new position in shares of ImmunityBio in the 2nd quarter valued at about $86,000. 8.58% of the stock is owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.